Neoadjuvant (neo) immune checkpoint blockade (ICB) in patients (Pts) with high-risk resectable metastatic melanoma (MM).

Rodabe Navroze Amaria,Sangeetha Reddy,Hussein Abdul-Hassan Tawbi,Michael A. Davies,Merrick I. Ross,Isabella Claudia Glitza,Janice Nicole Cormier,Carol M. Lewis,Wen-Jen Hwu,Ehab Y Hanna,Adi Diab,Michael K. K. Wong,Richard E. Royal,Neil D. Gross,Randal S. Weber,Stephen Yenzen Lai,Richard A. Ehlers,Elizabeth Burton,Michael T. Tetzlaff,Jennifer A. Wargo

Neoadjuvant (neo) immune checkpoint blockade (ICB) in patients (Pts) with high-risk resectable metastatic melanoma (MM).

2018

9510Background: Nivolumab (nivo) and combination ipilimumab (ipi) + nivo are highly active in pts with unresectable and stage IV MM. Nivo is also safe and effective adjuvant treatment for MM pts wi...

Keywords:

Melanoma
Blockade
Cancer research
Pathology
Medicine
Immune checkpoint
metastatic melanoma
Adjuvant
in patient
stage iv
Oncology
Internal medicine
Nivolumab
Ipilimumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations